Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay
This study demonstrates the feasibility of MRD detection in EBC using a plasma-only multiomic ctDNA-based approach. Larger studies are ongoing to further validate the clinical performance of the assay and demonstrate its applications.
Authors
- J. Huober
- F. Mehmeti
- Lisa Wiesmüller (ORCID: https://orcid.org/0000-0002-2397-5041)
- Franziska Mergel
- Sophia Huesmann
- Thomas W. P. Friedl (ORCID: https://orcid.org/0000-0002-4773-8067)
- Wolfgang Janni (ORCID: https://orcid.org/0000-0001-5911-2400)
- Kerstin Pfister
- AD Hartkopf
- Thereasa A. Rich (ORCID: https://orcid.org/0000-0003-3023-6930)
- Derek Dustin (ORCID: https://orcid.org/0000-0002-3566-0282)
- Aaron S. Fink
- T. Braun (ORCID: https://orcid.org/0000-0002-6012-2742)
- Tanja Fehm (ORCID: https://orcid.org/0000-0002-4926-0108)
- Volkmar Mueller (ORCID: https://orcid.org/0000-0003-4231-7906)
- Siyuan Zhang (ORCID: https://orcid.org/0000-0003-0910-3666)
- A de Gregorio
- B Rack
- N. Uhl
Institutions
- Universität Hamburg (DE)
- University of St.Gallen (CH)
- Düsseldorf University Hospital (DE)
- Guardant (United States) (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital Ulm (DE)
- SLK-Kliniken Heilbronn (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104296
- Citations
- 19
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 17.79